Low molecular weight, non-peptidic agonists of TrkA receptor with NGF-mimetic activity

Cell Death and Disease

Volumn 3, Issue 7, 2012, Pages

  Scarpi, D ^a   Cirelli, D ^a   Matrone, C ^b   Castronovo, G ^a   Rosini, P ^a   Occhiato, E G ^a   Romano, F ^a   Bartali, L ^a   Clemente, A M ^a   Bottegoni, G ^c   Cavalli, A ^c   De Chiara, G ^d   Bonini, P ^a   Calissano, P ^b   Palamara, A T ^d   Garaci, E ^e   Torcia, M G ^a   Guarna, A ^a   Cozzolino, F ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b EUROPEAN BRAIN RESEARCH INSTITUTE   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

apoptosis; MAP kinases; nerve growth factor; peptidomimetics; TRK A

Indexed keywords

AMINO ACID; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; NERVE GROWTH FACTOR; PEPTIDOMIMETIC AGENT; PROTEIN KINASE B; PROTEIN TYROSINE KINASE A; TYROSINE; AZEPINE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE 3; RECOMBINANT PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTOPHOSPHORYLATION; BINDING SITE; CELL ASSAY; CELL DIFFERENTIATION; CELL STRAIN; CELL SURVIVAL; DRUG ACTIVITY; DRUG BINDING; DRUG SYNTHESIS; HIPPOCAMPUS; HUMAN; HUMAN CELL; MOLECULAR WEIGHT; NERVE CELL; NEUROBIOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SERUM; ANIMAL; CELL STRAIN 3T3; CHEMISTRY; CYTOLOGY; DRUG EFFECT; DRUG POTENTIATION; GENETICS; METABOLISM; MOUSE; PHOSPHORYLATION; PROTEIN TERTIARY STRUCTURE; TUMOR CELL LINE;

ANIMALS; AZEPINES; BINDING SITES; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL SURVIVAL; HIPPOCAMPUS; HUMANS; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MOLECULAR WEIGHT; NERVE GROWTH FACTOR; NIH 3T3 CELLS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PC12 CELLS; PHOSPHORYLATION; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RECEPTOR, TRKA; RECOMBINANT PROTEINS;

EID: 84864885605     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2012.80     Document Type: Article

References (40)

1. Reichardt L.F. Neurotrophin-regulated signalling pathways. Philos Trans R Soc Lond B Biol Sci 2006; 361: 1545-1564.
2. Caporali A, Emanueli C. Cardiovascular actions of neurotrophins. Physiol Rev 2009; 89: 279-308.
3. Barker P.A. High affinity not in the vicinity? Neuron 2007; 53: 1-4.
4. Wehrman T, He X, Raab B, Dukipatti A, Blau H, Garcia K.C. Structural and mechanistic insights into nerve growth factor interactions with the TrkA and p75 receptors. Neuron 2007; 53: 25-38.
5. Wiesmann C, Ultsch MH, Bass SH, de Vos A.M. Crystal structure of nerve growth factor in complex with the ligand-binding domain of the TrkA receptor. Nature 1999; 401: 184-188.
6. de Pablo Y, Perez-Garcia MJ, Georgieva MV, Sanchis D, Lindqvist N, Soler RM et al. Tyr-701 is a new regulatory site for neurotrophin receptor TrkA trafficking and function. J Neurochem 2008; 104: 124-139.
7. Calissano P, Amadoro G, Matrone C, Ciafre S, Marolda R, Corsetti V et al. Does the term 'trophic' actually mean anti-amyloidogenic? The case of NGF. Cell Death Differ 2010; 17: 1126-1133.
8. Chao MV, Rajagopal R, Lee F.S. Neurotrophin signalling in health and disease. Clin Sci (Lond) 2006; 110: 167-173.
9. Liskamp RM, Rijkers DT, Kruijtzer JA, Kemmink J. Peptides and proteins as a continuing exciting source of inspiration for peptidomimetics. Chembiochem 2011; 12: 1626-1653.
10. Guarna A, Guidi A, Machetti F, Menchi G, Occhiato EG, Scarpi D, Sisi S, Trabocchi A, Synthesis and reactivity of bicycles derived from tartaric acid and α- amino acids: A novel class of conformationally constrained dipeptide isosteres based upon enantiopure 3-aza-6,8-dioxabicyclo[3.2.1] octane-7- carboxylic acid, 1999, Journal of Organic Chemistry, 64(20), 7347-7364
11. Trabocchi A, Menchi G, Guarna F, Machetti F, Scarpi D, Guarna A. Design, synthesis, and applications of 3-aza-6,8-dioxabicyclo[3.2.1] octane-based scaffolds for peptidomimetic chemistry. Synlett 2006; 331-353. (Pubitemid 43288564)
12. Guarna A, Cozzolino F, Torcia M, Garaci E. Pharmaceutical compositions for the treatment of diseases related to neurotrophines. PCT/EP2003/ 006471(7625892). 1-12-2009. 18-6-2003; Ref type: Patent.
13. Abagyan R, Totrov M. Biased probability Monte Carlo conformational searches and electrostatic calculations for peptides and proteins. J Mol Biol 1994; 235: 983-1002.
14. Levi A, Ferri GL, Watson E, Possenti R, Salton S.R. Processing, distribution, and function of VGF, a neuronal and endocrine peptide precursor. Cell Mol Neurobiol 2004; 24: 517-533.
15. Kim EK, Choi E.J. Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta 2010; 1802: 396-405.
16. Torcia M, De Chiara G, Nencioni L, Ammendola S, Labardi D, Lucibello M et al. Nerve growth factor inhibits apoptosis in memory B lymphocytes via inactivation of p38 MAPK, prevention of Bcl-2 phosphorylation, and cytochrome c release. J Biol Chem 2001; 276: 39027-39036.
17. Rosini P, De Chiara G, Bonini P, Lucibello M, Marcocci ME, Garaci E et al. Nerve growth factor-dependent survival of CESS B cell line is mediated by increased expression and decreased degradation of MAPK phosphatase 1. J Biol Chem 2004; 279: 14016-14023.
18. Vasudevan KM, Garraway L.A. AKT signaling in physiology and disease. Curr Top Microbiol Immunol 2010; 347: 105-133.
19. Owens DM, Keyse S.M. Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases. Oncogene 2007; 26: 3203-3213.
20. Matrone C, Ciotti MT, Mercanti D, Marolda R, Calissano P. NGF and BDNF signaling control amyloidogenic route and Abeta production in hippocampal neurons. Proc Natl Acad Sci USA 2008; 105: 13139-13144.
21. Kenchappa RS, Zampieri N, Chao MV, Barker PA, Teng HK, Hempstead BL et al. Liganddependent cleavage of the P75 neurotrophin receptor is necessary for NRIF nuclear translocation and apoptosis in sympathetic neurons. Neuron 2006; 50: 219-232.
22. Lu B, Pang PT, Woo N.H. The yin and yang of neurotrophin action. Nat Rev Neurosci 2005; 6: 603-614.
23. Ultsch MH, Wiesmann C, Simmons LC, Henrich J, Yang M, Reilly D et al. Crystal structures of the neurotrophin-binding domain of TrkA, TrkB and TrkC. J Mol Biol 1999; 290: 149-159.
24. Debeir T, Saragovi HU, Cuello A.C. A nerve growth factor mimetic TrkA antagonist causes withdrawal of cortical cholinergic boutons in the adult rat. Proc Natl Acad Sci USA 1999; 96: 4067-4072.
25. Beglova N, Maliartchouk S, Ekiel I, Zaccaro MC, Saragovi HU, Gehring K. Design and solution structure of functional peptide mimetics of nerve growth factor. J Med Chem 2000; 43: 3530-3540.
26. Xie Y, Tisi MA, Yeo TT, Longo F.M. Nerve growth factor (NGF) loop 4 dimeric mimetics activate ERK and AKT and promote NGF-like neurotrophic effects. J Biol Chem 2000; 275: 29868-29874.
27. Jang SW, Okada M, Sayeed I, Xiao G, Stein D, Jin P et al. Gambogic amide, a selective agonist for TrkA receptor that possesses robust neurotrophic activity, prevents neuronal cell death. Proc Natl Acad Sci USA 2007; 104: 16329-16334.
28. Colangelo AM, Bianco MR, Vitagliano L, Cavaliere C, Cirillo G, De Gioia L et al. A new nerve growth factor-mimetic peptide active on neuropathic pain in rats. J Neurosci 2008; 28: 2698-2709.
29. Fletcher JM, Morton CJ, Zwar RA, Murray SS, O'Leary PD, Hughes R.A. Design of a conformationally defined and proteolytically stable circular mimetic of brain-derived neurotrophic factor. J Biol Chem 2008; 283: 33375-33383.
30. Brahimi F, Malakhov A, Lee HB, Pattarawarapan M, Ivanisevic L, Burgess K et al. A peptidomimetic of NT-3 acts as a TrkC antagonist. Peptides 2009; 30: 1833-1839.
31. Massa SM, Yang T, Xie Y, Shi J, Bilgen M, Joyce JN et al. Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents. J Clin Invest 2010; 120: 1774-1785.
32. Liu J, Brahimi F, Saragovi HU, Burgess K. Bivalent diketopiperazine-based tropomysin receptor kinase C (TrkC) antagonists. J Med Chem 2010; 53: 5044-5048.
33. Matrone C, Marolda R, Ciafre S, Ciotti MT, Mercanti D, Calissano P. Tyrosine kinase nerve growth factor receptor switches from prosurvival to proapoptotic activity via Abeta-mediated phosphorylation. Proc Natl Acad Sci USA 2009; 106: 11358-11363.
34. Semenova MM, Maki-Hokkonen AM, Cao J, Komarovski V, Forsberg KM, Koistinaho M et al. Rho mediates calcium-dependent activation of p38alpha and subsequent excitotoxic cell death. Nat Neurosci 2007; 10: 436-443.
35. Filomeni G, Cardaci S, Costa Ferreira AM, Rotilio G, Ciriolo M.R. Metabolic oxidative stress elicited by the copper(II) complex [Cu(isaepy)2] triggers apoptosis in SH-SY5Y cells through the induction of the AMP-activated protein kinase/p38MAPK/p53 signalling axis: evidence for a combined use with 3-bromopyruvate in neuroblastoma treatment. Biochem J 2011; 437: 443-453.
36. Horbinski C, Chu C.T. Kinase signaling cascades in the mitochondrion: a matter of life or death. Free Radic Biol Med 2005; 38: 2-11.
37. Kaiser RA, Bueno OF, Lips DJ, Doevendans PA, Jones F, Kimball TF et al. Targeted inhibition of p38 mitogen-activated protein kinase antagonizes cardiac injury and cell death following ischemia-reperfusion in vivo. J Biol Chem 2004; 279: 15524-15530.
38. Meloni M, Caporali A, Graiani G, Lagrasta C, Katare R, Van Linthout S et al. Nerve growth factor promotes cardiac repair following myocardial infarction. Circ Res 2010; 106: 1275-1284.
39. Matrone C, Barbagallo AP, La Rosa LR, Florenzano F, Ciotti MT, Mercanti D et al. APP is phosphorylated by TrkA and regulates NGF/TrkA signaling. J Neurosci 2011; 31: 11756-11761.
40. An J, Totrov M, Abagyan R. Pocketome via comprehensive identification and classification of ligand binding envelopes. Mol Cell Proteomics 2005; 4: 752-761.